Quick Answer
ImageneBio, Inc. reported Research And Development Expense of $28.53 million for the year ending 2025.
- ImageneBio, Inc. showed a decrease of -11.2% in Research And Development Expense from 2024 to 2025.
- This data is from ImageneBio, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $7.89 million | Q2 2020: $6.33 million | Q3 2020: $7.22 million | Q1 2021: $10.02 million | Q2 2021: $11.37 million | Q3 2021: $13.38 million | Q1 2022: $14.34 million | Q2 2022: $15.49 million | Q3 2022: $18.85 million | Q1 2023: $15.55 million | Q2 2023: $15.17 million | Q3 2023: $14.65 million | Q1 2024: $9.65 million | Q2 2024: $9.83 million | Q3 2024: $3.89 million | Q1 2025: $3.72 million | Q2 2025: $4.03 million | Q3 2025: $15.56 million.
- Over the full 6 years of available data (2020 to 2025), ImageneBio, Inc.'s Research And Development Expense has declined by 36.4%.
- Historical annual values: Fiscal year 2025: $28.53 million | Fiscal year 2024: $32.11 million | Fiscal year 2023: $59.65 million | Fiscal year 2022: $64.32 million | Fiscal year 2021: $47.11 million | Fiscal year 2020: $44.85 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: